In models of prostate cancer, lycopene treatment induces a decrease in the concentration of inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-8, IL-10, and TGF-β associated with a reduction in tumor growth and an increase in survival [373]. Here, IL1B is linked to prostate carcinoma.